High quality in st...

High quality  in stock CAS NO.936091-26-8
High quality  in stock CAS NO.936091-26-8
High quality  in stock CAS NO.936091-26-8
High quality  in stock CAS NO.936091-26-8

High quality in stock CAS NO.936091-26-8

Min.Order / FOB Price:Get Latest Price

1 Kilogram

FOB Price:USD 1.0000 -3.0000

  • Min.Order :1 Kilogram
  • Purity: 99%
  • Payment Terms : T/T,,MoneyGram,Other

Keywords

936091-26-8 936091-26-8 TG 101348SAR302503 TG 101348SAR302503

Quick Details

  • Appearance:crystal, powder
  • Application:Pharmaceutical intermediates
  • PackAge:as your request
  • ProductionCapacity:10|Kilogram|Day
  • Storage:stay in dry, cool and well-sealed
  • Transportation:EMS,HK EMS,FEDEX,DHL,TNT

Superiority:

  • ProName: Cycloheptane-1,3-Dione
  • CasNo: 1194-18-9
  • Molecular Formula: C7H10O2
  • Appearance: Look at the detailed information
  • Application: intermediates
  • DeliveryTime: according to the clients requirement
  • PackAge: according to the clients requirement
  • Port: China Main Port
  • ProductionCapacity: 100 Metric Ton/Year
  • Purity: 95%, 99%
  • Storage: According to the characteristics of th...
  • Transportation: by sea or air
  • LimitNum: 100 Gram

Details:

TG101348 (SAR302503) is an orally available inhibitor of Janus kinase 2 (JAK-2) developed for the treatment of patients with myeloproliferative diseases including myelofibrosis. TG101348 acts as a competitive inhibitor of protein kinase JAK-2 with IC50=6 nM; related kinases FLT3 and RET are also sensitive, with IC50=25 nM and IC50=17 nM, respectively. Significantly less activity was observed against other tyrosine kinases including JAK3 (IC50=169 nM).[1] In treated cells the inhibitor blocks downstream cellular signalling (JAK-STAT) leading to suppression of proliferation and induction of apoptosis.

Myelofibrosis is a myeloid malignancy associated with anemia, splenomegaly, and constitutional symptoms. Patients with myelofibrosis frequently harbor JAK-STAT activating mutations that are sensitive to TG101348. Phase I trial results focused on safety and efficacy of TG101348 in patients with high- or intermediate-risk primary or post–polycythemia vera/essential thrombocythemia myelofibrosis have been published in 2011.

 

Our advangtage:

 
Many years experience in research chemical area
Credit first, rational price, customer foremost, excellent quality
professional service
Store in bulk
Sample supply
Synthesis acceptable
Safe shipping

Related Searches

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View